Q2 Report 2026

For Q2 2026, Net Revenue was 29,787,221 while Profit After Financial Items was -1,352,445 and EPS was -0.03, indicating continued losses. On a year-to-date basis, H1 2026 Net Revenue reached 57,312,664 with H1 Profit After Financial Items of -3,610,503 and EPS of -0.07. The Equity Ratio remains deeply negative at -69%, reflecting weak balance-sheet footing.

Analysis

The balance sheet, not the reported EBITDA line, is the real signal here. A company can show operating earnings and still destroy equity value if interest, leases, or other financing costs consume the margin of safety; negative equity also implies that any refinancing will be priced off lender confidence rather than reported growth. In that setup, the equity behaves more like an out-of-the-money call on a rescue rather than a normal operating business.

The second-order effect is supplier and lender tightening. Once counterparties see a deeply negative equity base, they often shorten payment terms, require deposits, or reprice credit lines, which can convert an accounting loss into a liquidity problem within 1-3 quarters. That usually benefits better-capitalized peers in the same industry because they can take share on service reliability and terms while the distressed name is forced to defend cash.

The contrarian risk is that this may be a financing-heavy, asset-light model where EBITDA is a meaningful leading indicator and the below-EBITDA charges are mostly one-offs. The thesis is falsified if operating cash flow is positive, debt maturities are pushed out without punitive dilution, or management can show a clear path to equity repair. Absent that, the likely path over 6-18 months is either dilution, asset sales, or restructuring rather than clean fundamental re-rating.

Key Decisions for Investors

• No immediate long: wait for cash-flow-from-operations, debt maturity, and covenant disclosure before adding exposure; the current data only supports a distress watch, not a conviction short.
• If this is a listed micro/small-cap, express the quality-vs-leverage view with a factor pair: long QUAL / short IWM for 1-3 months; thesis breaks if credit spreads tighten materially or small caps outperform on easing-rate expectations.
• If the stock rallies on headline EBITDA strength, fade the move into the next financing or earnings event; use puts or a small short only if management confirms negative free cash flow and no credible refinancing path.
• Watch for equity repair actions in the next 1-3 months: recapitalization, asset sale, covenant waiver, or dilutive placement; any successful, non-dilutive refinancing would be the clearest thesis falsifier.
• Screen competitors with cleaner balance sheets for share gains over the next 6-18 months; distressed suppliers typically lose pricing power before revenue visibly deteriorates.